BioSpace News Archive

American Medical Technologies (AMT), the leading independent provider of wound care solutions for long-term care and post-acute environments, has partnered with TillaCare to introduce UriCap, an innovative external urine collection device for managing female urinary incontinence (UI) in the long-term care market across the United States.

Sunovion Pharmaceuticals Inc. (Sunovion) today announced the resubmission of the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for apomorphine sublingual film (APL-130277) to treat motor fluctuations (OFF episodes) experienced by people living with Parkinson’s disease (PD) in response to the January 29, 2019 Complete Response Letter (CRL).

Vivify Health, the developer of the nation’s leading connected care platform for holistic patient care and engagement, announced that it has been named a winner of the 29th Annual SMU Cox Dallas 100™ Awards

InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) today announced the closing of its previously announced public offering of 7,000,000 shares of its common stock, par value $0.00001 per share, at a price to the public of $0.12 per share.

Technavio has announced its latest market research report titled global in-vitro colorectal cancer screening tests market 2019-2023.

Industry expert judges and attendees picked the four winners of the Oregon Bioscience Association’s 2019 Research Fast Pitch and Company Pitch Fest competition

Zoetis Inc. announced the acquisition of ZNLabs, a full-service veterinary clinical reference laboratory company with a network of labs across the U.S.

Heartseed (Heartseed Inc.), a Tokyo-based biotechnology company developing iPSC-derived cardiomyocytes for the treatment of heart failure (HF), today announced it has raised 2.8 Billion-yen (approx. $26 Million) at Series B round, bringing its total financial backing to 3.8 Billion yen (approx. $35 Million) since it was founded in 2015.

Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, today announced that it has extended its collaboration agreement with GlaxoSmithKline plc (

Emergent BioSolutions Inc. (NYSE:EBS) announced updated results from the interim analysis of its Phase 2 clinical study evaluating the safety and immunogenicity of the company’s chikungunya virus virus-like particle (CHIKV VLP) vaccine candidate across a series of dosing regimens